Flag of the European Union EU Clinical Trials Register Help

Clinical trials for End stage pulmonary disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    196 result(s) found for: End stage pulmonary disease. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-003184-31 Sponsor Protocol Number: Hx-CD20-408 Start Date*: 2007-05-31
    Sponsor Name:Genmab A/S
    Full Title: A double-blind, randomized, placebo-controlled, multi-center, Clinical Trial of ofatumumab, a fully human monoclonal anti-CD20 antibody in patients with moderate to severe stage Chronic Obstructive...
    Medical condition: Moderate to severe stage of Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020141-26 Sponsor Protocol Number: D3320C00001 Start Date*: 2010-08-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an oral tablet in Subjects with Mild COPD Following Seg...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000413-36 Sponsor Protocol Number: WHRC_P37644 Start Date*: 2012-04-27
    Sponsor Name:Imperial College
    Full Title: ACE-EPIC: ACE inhibitors to enhance the effects of pulmonary rehabilitation in COPD
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001008-23 Sponsor Protocol Number: RIOP-1 Start Date*: 2014-09-26
    Sponsor Name:The Newcastle Upon Tyne Hospital NHS Foundation Trust, Freeman Hospital
    Full Title: Riociguat in patients with respiratory disease and hypoxia – a proof-of-concept study
    Medical condition: Pulmonary hypertension WHO Group III (Pulmonary hypertension owing to lung disease and/or hypoxia): Chronic obstructive pulmonary disease(COPD); Pulmonary Fibrosis (PF).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000207-13 Sponsor Protocol Number: 2012RC22 Start Date*: 2015-09-17
    Sponsor Name:Tayside Clinical Trials Unit, University of Dundee
    Full Title: Proof of concept study to assess the differential effects of chronic beta-blockade (celiprolol versus bisoprolol) on cardiopulmonary outcomes at rest and during exercise in chronic obstructive pulm...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10009026 Chronic obstructive airways disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002192-35 Sponsor Protocol Number: 19225 Start Date*: 2020-10-13
    Sponsor Name:Bayer - AG
    Full Title: A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of BAY 2327949 in patients with chronic kidney disease (eGFR range from 25 to 60 mL/min/1.73 m²)...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) NO (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008192-34 Sponsor Protocol Number: ERD-01-08/EP Start Date*: 2009-08-13
    Sponsor Name:EDMOND PHARMA S.R.L.
    Full Title: THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomized, double-blind, placebo-controlled, parallel group, multicenter...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 SOC
    9.1 10029978 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) CZ (Completed) FR (Completed) DK (Completed) SK (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-000727-26 Sponsor Protocol Number: HZC111348 Start Date*: 2008-07-15
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000724-12 Sponsor Protocol Number: D0520C00002 Start Date*: 2008-06-05
    Sponsor Name:AstraZeneca AB
    Full Title: A 2-week, randomised, double-blind, placebo-controlled, parallel group study to assess the tolerability and pharmacokinetics of orally administered AZD9668 in patients with COPD
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006276-38 Sponsor Protocol Number: A4471008 Start Date*: 2007-06-27
    Sponsor Name:Boehring Ingelheim Pharma Ges mbH, Regional Division Medicine, Regional Centre Vienna
    Full Title: A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18 MCG of Tiotropium inhalation capsules administered by Handihaler® once-daily plu...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) GB (Completed) BE (Completed) GR (Completed) PT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012546-23 Sponsor Protocol Number: CCD-0906-PR-0016 Start Date*: 2009-10-02
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 48-WEEK, DOUBLE BLIND, RANDOMIZED, MULTINATIONAL, MULTICENTRE, 2-ARM PARALLEL GROUP, REFERENCE TREATMENT CONTROLLED CLINICAL TRIAL OF “FIXED COMBINATION” BECLOMETHASONE DIPROPIONATE PLUS FORMOTER...
    Medical condition: Severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) GB (Completed) CZ (Completed) AT (Completed) ES (Completed) FR (Completed) IT (Completed) HU (Completed) NL (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-013235-38 Sponsor Protocol Number: CQVA149A2307 Start Date*: 2010-03-25
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, double-blind, placebocontrolled study, to assess the long term safety of 52 weeks treatment with QVA149 (110μg indacaterol / 50μg glycopyrrolate) in patients with moderat...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) GB (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005641-17 Sponsor Protocol Number: 2019/ABM/01/00074 Start Date*: 2021-10-12
    Sponsor Name:Medical University of Bialystok
    Full Title: Non-commercial clinical trial of statins CAncer preventive and Pleiotropic TherApy IN smokers with chronic obstructive pulmonary disease (COPD) Clinical part: Atorvastatin effect on reduction of CO...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    27.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004870-26 Sponsor Protocol Number: CQVA149ADE01 Start Date*: 2012-03-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 26-week treatment, multicenter, randomized, parallel group, blinded study to assess the efficacy and safety of QVA149 (110/50 µg q.d.) in patients with moderate to severe chronic obstructive pulm...
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000381-11 Sponsor Protocol Number: CCMK389X2201 Start Date*: 2020-06-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sar...
    Medical condition: Chronic pulmonary sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037430 Pulmonary sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004949-32 Sponsor Protocol Number: 0091 Start Date*: 2013-02-12
    Sponsor Name:Theravance, Inc.
    Full Title: A Phase 2, Randomised, Double-Blind, Multiple−Dose, Five−Period, Incomplete-Block, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Multiple Doses o...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) - GOLD stage 2 or 3
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    14.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004031-31 Sponsor Protocol Number: RVH006 Start Date*: 2011-11-15
    Sponsor Name:RespiVert Ltd
    Full Title: A randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of treatment with repeat doses of inhaled RV568 in patients with COPD.
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014586-75 Sponsor Protocol Number: D0520C00020 Start Date*: 2009-12-21
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60 mg AZD9668 Administered Orally Twice Daily to Subje...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005249-51 Sponsor Protocol Number: A7881013 Start Date*: 2010-05-19
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent UK
    Full Title: A PHASE 2B, PARALLEL, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE COMPARATOR AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND EFFICACY OF 6-WEEK QD ADMINISTRATION OF PF-00610355 CRC-74...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) EE (Completed) BG (Completed) PL (Completed) DE (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-001633-40 Sponsor Protocol Number: ESRA Start Date*: 2022-03-07
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial Hypertension Doubleblind, randomized, multicentre, multinational, pla...
    Medical condition: early pulmonary vascular disease, defined as either a) mean pulmonary arterial pressure (mPAP) ≥25 mmHg with pulmonary vascular resistance (PVR) ≥2 to <3 WU and pulmonary arterial wedge pressure (P...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037455 Pulmonary vascular disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 16:02:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA